Analyzing Corbus Pharmaceuticals Holdings (CRBP) and Its Peers

Corbus Pharmaceuticals Holdings (NASDAQ: CRBP) is one of 282 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its rivals? We will compare Corbus Pharmaceuticals Holdings to similar companies based on the strength of its risk, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Corbus Pharmaceuticals Holdings and its rivals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Corbus Pharmaceuticals Holdings 0 0 4 0 3.00
Corbus Pharmaceuticals Holdings Competitors 808 3173 11491 230 2.71

Corbus Pharmaceuticals Holdings presently has a consensus price target of $20.75, indicating a potential upside of 192.25%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 42.35%. Given Corbus Pharmaceuticals Holdings’ stronger consensus rating and higher probable upside, analysts plainly believe Corbus Pharmaceuticals Holdings is more favorable than its rivals.

Profitability

This table compares Corbus Pharmaceuticals Holdings and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Corbus Pharmaceuticals Holdings -1,040.41% -96.02% -77.38%
Corbus Pharmaceuticals Holdings Competitors -5,343.91% -435.46% -40.90%

Valuation & Earnings

This table compares Corbus Pharmaceuticals Holdings and its rivals top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue NetIncome Price/Earnings Ratio
Corbus Pharmaceuticals Holdings $1.91 million -$19.99 million -11.45
Corbus Pharmaceuticals Holdings Competitors $286.20 million $34.74 million 141.25

Corbus Pharmaceuticals Holdings’ rivals have higher revenue and earnings than Corbus Pharmaceuticals Holdings. Corbus Pharmaceuticals Holdings is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Institutional and Insider Ownership

28.7% of Corbus Pharmaceuticals Holdings shares are owned by institutional investors. Comparatively, 48.9% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 11.9% of Corbus Pharmaceuticals Holdings shares are owned by company insiders. Comparatively, 17.3% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Risk & Volatility

Corbus Pharmaceuticals Holdings has a beta of 183.73, indicating that its share price is 18,273% more volatile than the S&P 500. Comparatively, Corbus Pharmaceuticals Holdings’ rivals have a beta of 7.27, indicating that their average share price is 627% more volatile than the S&P 500.

Corbus Pharmaceuticals Holdings Company Profile

Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment. The Company’s product, anabasum is a synthetic oral endocannabinoid-mimetic drug that is designed to resolve chronic inflammation and halt fibrotic processes without causing immunosuppression. Anabasum stimulates the production of Specialized Pro-Resolving Lipid Mediators (SPMs) that act to resolve inflammation, and halt fibrosis by activating endogenous pathways. The Company is developing anabasum to treat four diseases: systemic sclerosis, cystic fibrosis, diffuse cutaneous, skin-predominant dermatomyositis and systemic lupus erythematosus (SLE).

Receive News & Ratings for Corbus Pharmaceuticals Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply